{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:42:56Z","timestamp":1740163376183,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s13555-024-01299-6","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T08:47:45Z","timestamp":1730969265000},"page":"3229-3241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Ploysyne","family":"Rattanakaemakorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parawee","family":"Chevaisrakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanisada","family":"Wongpraparut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveena","family":"Chiowchanwisawakit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Napatra","family":"Tovanabutra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pimchanok","family":"Tantiwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warayuwadee","family":"Amornpinyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panlop","family":"Chakkavittumrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Punchong","family":"Hanvivadhanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumapa","family":"Chaiamnuay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supapat","family":"Laodheerasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bensachee","family":"Pattamadilok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charoen","family":"Choonhakarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajanee","family":"Mahakkanukrauh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duangkamol","family":"Aiewruengsurat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siripan","family":"Sangmala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisa","family":"Pretikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kittiwan","family":"Sumethkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panchalee","family":"Satpanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metavee","family":"Boonsiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruemon","family":"Sangob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2628-0894","authenticated-orcid":false,"given":"Pravit","family":"Asawanonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of PROMPT Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"1299_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301\u201315.","journal-title":"Lancet"},{"key":"1299_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/BOR.0000000000000475","volume":"30","author":"R Wang","year":"2018","unstructured":"Wang R, Ward MM. Epidemiology of axial spondyloarthritis. Curr Opin Rheumatol. 2018;30:137\u201343.","journal-title":"Curr Opin Rheumatol"},{"key":"1299_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/imm.13242","volume":"161","author":"A Voruganti","year":"2020","unstructured":"Voruganti A, Bowness P. New developments in our understanding of ankylosing spondylitis pathogenesis. Immunol. 2020;161:94\u2013102.","journal-title":"Immunol"},{"key":"1299_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/1346-8138.13806","volume":"44","author":"J Zeng","year":"2017","unstructured":"Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44:863\u201372.","journal-title":"J Dermatol"},{"key":"1299_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/ijr.11.64","volume":"7","author":"E Avalos-D\u00edaz","year":"2012","unstructured":"Avalos-D\u00edaz E, Dom\u00ednguez-Cherit J, Herrera-Esparza R. Cutaneous manifestations of spondyloarthritis. J Clin Rheumatol. 2012;7:55\u201361.","journal-title":"J Clin Rheumatol"},{"key":"1299_CR6","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1097\/RHU.0000000000001575","volume":"27","author":"JA Walsh","year":"2021","unstructured":"Walsh JA, Magrey M. Clinical manifestations and diagnosis of axial spondyloarthritis. J Clin Rheumatol. 2021;27:e547\u201360.","journal-title":"J Clin Rheumatol"},{"key":"1299_CR7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/jdv.12355","volume":"28","author":"M Eskin","year":"2014","unstructured":"Eskin M, \u015eavk E, Uslu M, K\u00fc\u00e7\u00fckaydo\u011fan N. Social problem-solving, perceived stress, negative life events, depression and life satisfaction in psoriasis. J Eur Acad Dermatol. 2014;28:1553\u20139.","journal-title":"J Eur Acad Dermatol"},{"key":"1299_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80:251\u201365.","journal-title":"J Am Acad Dermatol"},{"key":"1299_CR9","first-page":"663","volume":"28","author":"N Garg","year":"2014","unstructured":"Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Rheumatol. 2014;28:663\u201372.","journal-title":"Rheumatol"},{"key":"1299_CR10","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.3390\/ijms21176401","volume":"21","author":"H Tsukazaki","year":"2020","unstructured":"Tsukazaki H, Kaito T. The role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis. Int J Mol Sci. 2020;21:6401.","journal-title":"Int J Mol Sci"},{"key":"1299_CR11","unstructured":"Aboobacker S, Kurn H, Al Aboud AM. Secukinumab. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/30725776\/. Accessed 2024 Jun 18."},{"key":"1299_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2014results of two phase\u00a03 trials. N Engl J Med. 2014;371:326\u201338.","journal-title":"N Engl J Med"},{"key":"1299_CR13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet"},{"key":"1299_CR14","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705\u201313.","journal-title":"Lancet"},{"key":"1299_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03051-5","author":"J Braun","year":"2023","unstructured":"Braun J, Blanco R, Marzo-Ortega H, et al. Two-year imaging outcomes from a phase\u00a03 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis. Arthritis Res Ther. 2023. https:\/\/doi.org\/10.1186\/s13075-023-03051-5.","journal-title":"Arthritis Res Ther"},{"key":"1299_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Blanco R, Dokoupilov\u00e1 E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized placebo-controlled phase\u00a0III study. Arthritis Rheumatol. 2020;73:110\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"1299_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02613-9","author":"J Braun","year":"2021","unstructured":"Braun J, Blanco R, Marzo-Ortega H, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase\u00a0III study PREVENT. Arthritis Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13075-021-02613-9.","journal-title":"Arthritis Res Ther"},{"key":"1299_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/09546630310013360","volume":"14","author":"S Weisman","year":"2003","unstructured":"Weisman S, Pollack C, Gottschalk R. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14:158\u201365.","journal-title":"J Dermatolog Treat"},{"key":"1299_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RGB Langley","year":"2013","unstructured":"Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2013;26:23\u201331.","journal-title":"J Dermatolog Treat"},{"key":"1299_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1299_CR21","first-page":"2262","volume":"32","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Mease PJ, Krueger G, et al. Outcome measures in psoriatic arthritis. J Rheumatol. 2005;32:2262\u20139.","journal-title":"J Rheumatol"},{"key":"1299_CR22","first-page":"S64","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis: tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesit. Arthritis Care Res. 2011;63:S64\u201385.","journal-title":"Arthritis Care Res"},{"key":"1299_CR23","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1002\/acr.20543","volume":"63","author":"GA Hawker","year":"2011","unstructured":"Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 2011;63:S240\u201352.","journal-title":"Arthritis Care Res"},{"key":"1299_CR24","first-page":"S47","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Bath Ankylosing Sp Arthritis Care Res. 2011;63:S47\u201358.","journal-title":"Bath Ankylosing Sp Arthritis Care Res"},{"key":"1299_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15958","author":"P Asawanonda","year":"2022","unstructured":"Asawanonda P, Pattamadilok B, Chularojanamontri L, et al. Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: characteristics, effectiveness, and safety. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15958.","journal-title":"Dermatol Ther"},{"key":"1299_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13555-022-00867-y","volume":"13","author":"HT Nguyen","year":"2023","unstructured":"Nguyen HT, Pham NTU, Tran TNA, Pham NN, Bui YT, Vu TTP. Long-term effectiveness and drug survival of secukinumab in Vietnamese patients with psoriasis: results from a retrospective ENHANCE study. Dermatol Ther. 2023;13:465\u201376.","journal-title":"Dermatol Ther"},{"key":"1299_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27\u201336.","journal-title":"J Am Acad Dermatol"},{"key":"1299_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1299_CR29","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5\u00a0years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32:1507\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1299_CR30","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329\u201339.","journal-title":"N Engl J Med"},{"key":"1299_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018. https:\/\/doi.org\/10.1186\/s13075-018-1551-x.","journal-title":"Arthritis Res Ther"},{"key":"1299_CR32","first-page":"393","volume":"6","author":"AJ Kivitz","year":"2019","unstructured":"Kivitz AJ, Nash P, Tahir H, et al. Efficacy and safety of subcutaneous secukinumab 150\u00a0mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Arthritis Res Ther. 2019;6:393\u2013407.","journal-title":"Arthritis Res Ther"},{"key":"1299_CR33","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase\u00a03b trial. Lancet. 2020;395:1496\u2013505.","journal-title":"Lancet"},{"key":"1299_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001600","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Landew\u00e9 R, Rahman P, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021. https:\/\/doi.org\/10.1136\/rmdopen-2021-001600.","journal-title":"RMD Open"},{"key":"1299_CR35","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/acr.23233","volume":"69","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase\u00a0III study. Arthritis Care Res. 2017;69:1020\u20139.","journal-title":"Arthritis Care Res"},{"key":"1299_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase\u00a03 study, MEASURE 3. Arthritis Res Ther. 2017. https:\/\/doi.org\/10.1186\/s13075-017-1490-y.","journal-title":"Arthritis Res Ther"},{"key":"1299_CR37","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","volume":"133","author":"F Huang","year":"2020","unstructured":"Huang F, Sun F, Wan Wei Guo, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, phase\u00a0III China-centric study MEASURE 5. Chin Med J. 2020;133:2521\u201331.","journal-title":"Chin Med J"},{"key":"1299_CR38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","volume":"5","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150\u00a0mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018;5:447\u201362.","journal-title":"Rheumatol Ther"},{"key":"1299_CR39","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s12325-020-01352-8","volume":"37","author":"U Kiltz","year":"2020","unstructured":"Kiltz U, Sfikakis PP, Gaffney K, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. Adv Therapy. 2020;37:2865\u201383.","journal-title":"Adv Therapy"},{"key":"1299_CR40","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med"},{"key":"1299_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/ajd.13895","volume":"63","author":"P Foley","year":"2022","unstructured":"Foley P, Manuelpillai N, Dolianitis Con, et al. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study). Australas J Dermatol. 2022;63:303\u201311.","journal-title":"Australas J Dermatol"},{"key":"1299_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s13555-022-00849-0","volume":"13","author":"KA Papp","year":"2022","unstructured":"Papp KA, Gooderham M, Dei-Cas I, et al. Effectiveness and safety of secukinumab in Latin American patients with moderate to severe plaque psoriasis: PURE registry 12-month data. Dermatol Ther. 2022;13:269\u201383.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01299-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01299-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01299-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:48:39Z","timestamp":1732855719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01299-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01299-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ploysyne Rattanakaemakorn, Parawee Chevaisrakul, Chanisada Wongpraparut, Praveena Chiowchanwisawakit, Napatra Tovanabutra, Pimchanok Tantiwong, Warayuwadee Amornpinyo, Panlop Chakkavittumrong, Punchong Hanvivadhanakul, Sumapa Chaiamnuay, Supapat Laodheerasiri, Bensachee Pattamadilok, Charoen Choonhakarn, Ajanee Mahakkanukrauh, Duangkamol Aiewruengsurat, Siripan Sangmala, Nisa Pretikul, Kittiwan Sumethkul, Panchalee Satpanich, Metavee Boonsiri, Naruemon Sangob, Pravit Asawanonda have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The Central Research Ethics Committee (COA-CREC 075\/2022) and the local institutional review board (IRB) of each participating institution approved the study\u2019s protocol. All patients were required to provide written informed consent and authorization prior to participating.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}